Ananda Mohan Chakrabarty (Bengali: আনন্দমোহন চক্রবর্তী Ānandamōhan Cakrabartī), PhD (4 April 1938 – 10 July 2020) was an Indian American microbiologist, scientist, and researcher, most notable for his work in directed evolution and his role in developing a genetically engineered organism using plasmid transfer while working at GE, the patent for which[3] led to landmark Supreme Court case, Diamond v. Chakrabarty.

By irradiating the transformed organism with UV light after plasmid transfer, Prof. Chakrabarty discovered a method for genetic cross-linking that fixed all four plasmid genes in place and produced a new, stable, bacterial species (now called Pseudomonas putida) capable of consuming oil one or two orders of magnitude faster than the previous four strains of oil-eating microbes.

The new microbe, which Chakrabarty called "multiplasmid hydrocarbon-degrading Pseudomonas," could digest about two-thirds of the hydrocarbons that would be found in a typical oil spill.

Chakrabarty's landmark research has since paved the way for many patents on genetically modified micro-organisms and other life forms, and catapulted him into the international spotlight.

[12] His lab worked on elucidating the role of bacterial cupredoxins and cytochromes in cancer regression and arresting cell cycle progression.

[13] In 2001, Prof. Chakrabarty founded a company, CDG Therapeutics,[12][14] (incorporated in Delaware) which holds proprietary information related to five patents generated by his work at the University of Illinois at Chicago.

[12] In 2008, Prof. Chakrabarty co-founded a second biopharmaceutical discovery company, Amrita Therapeutics Ltd., registered in Ahmedabad, Gujarat, to develop therapies, vaccines, and diagnostics effective against cancers and/or other major public health threats derived from bacterial products found in the human body.